Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Psilocybin - Braxia Scientific

X
Drug Profile

Psilocybin - Braxia Scientific

Alternative Names: Psilocybin- Braxia Scientific

Latest Information Update: 08 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Braxia Scientific
  • Class Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Small molecules
  • Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Depressive disorders

Most Recent Events

  • 22 Jul 2023 Braxia Scientific completes a phase II trials in Depressive disorders in Canada (unspecified route) (NCT05029466)
  • 02 Dec 2022 Braxia completes enrolment in its Phase II- clinical trials in Depressive disorders in Canada (unspecified route)
  • 29 Aug 2022 Health Canada approves multiple Special Access Program (SPA) applications to provide psilocybin-assisted psychotherapy for major depressive disorder prior to August 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top